News
10-04-2015, 11:00 PM
OBI Pharma, Inc. today announced an agreement with MSD, known as Merck in the United States and Canada, through a subsidiary transferring exclusive rights to develop and commercialize Dificid (fidaxomicin) in Taiwan to MSD.
More... (http://www.news-medical.net/news/20151005/OBI-Pharma-transfers-exclusive-rights-to-develop-commercialize-Dificid-(fidaxomicin)-in-Taiwan-to-MSD.aspx)
More... (http://www.news-medical.net/news/20151005/OBI-Pharma-transfers-exclusive-rights-to-develop-commercialize-Dificid-(fidaxomicin)-in-Taiwan-to-MSD.aspx)